Business
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Monday, March 10, 2025 at 2:20 PM EST at the Leerink Partners Global Healthcare Conference in Miami, Florida. A live webcast and replay of the fireside chat will be available on the Events & Presentat
About this update from Pyxis Oncology, Inc.
[{"type":"image","alt":"Pyxis Oncology","displaySize":"","headline":null,"caption":"Pyxis Oncology","className":"","disableSlideshowImg":false,"size":{"original":{"width":203,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/c663fbbdcef74ec76700a29d86aa098c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IX0t534d6HFsYbdc2gj8WA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE4NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c663fbbdcef74ec76700a29d86aa098c","width":203,"height":105}},"lazy":false},{"type":"text","content":"BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Monday, March 10, 2025 at 2:20 PM EST at the Leerink Partners Global Healthcare Conference in Miami, Florida.","length":409,"tagName":"p"},{"type":"text","content":"A live webcast and replay of the fireside chat will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.","length":188,"tagName":"p"},{"type":"text","content":"About Pyxis Oncology, Inc.Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN, a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-201 is designed to directly kill cancer cells and to address factors in the microenvironment that enable the uncontrolled proliferation and immune evasion of malignant tumors.","length":671,"tagName":"p"},{"type":"text","content":"To learn more, visit www.pyxisoncology.com or follow us on X (formerly known as Twitter) and LinkedIn.","length":132,"tagName":"p"},{"type":"text","content":"Pyxis Oncology ContactPamela Connealy CFO and COO [email protected]","length":73,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]